COMPANY
Clinical Phase 2
Keywords: antibody monoclonal antibody Thyroid Eye Disease Graves Ophthalmopathy Graves Orbitopathy Thyroid Associated Ophthalmopathy Endocrine System Diseases Orbital Diseases Proptosis Eye Diseases LASN01
Location: San Diego, CA · source · Oct 13, 2026
Profile checked Oct 10, 2026
Raises and deals from press releases
- Raise Series B · $85M · announced Dec 19, 2023 Company release ↗
Source quote
- Dec 19, 2023 · Company release ↗
“19 December 2023 | Lassen Therapeutics Announces Closing of Oversubscribed $85 Million Series B”
Raises announced in these releases: $85M disclosed.
From the company’s own releases; this list is partial. All raises and deals
Timeline
- Trial start Phase 2: A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease source ↗
- Raise Series B · $85M source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT06226545 | A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease | Phase 2 | Completed | Mar 5, 2024 | Apr 22, 2025 (actual) |
